

MENTAL DISORDERS AND HEPATITIS C PREVALENCE IN PEOPLE ON OPIOID AGONISTE THERAPY FOLLOWED AT THE SAMMSU COHORT, SWITZERLAND.

Castro E¹, Gueorguiev B², Bregenzer A³, Bruggmann P⁴, Della Santa P⁵, Hensel-Koch K⁶, Moriggia A⁷, Thurnheer MC⁸, Scheidegger C⁹, Combescure C¹⁰ and Girardin F¹¹

¹Private Practice, and HepC Virtual Clinic, Lausanne, Switzerland

²Geneva University, Geneva, Switzerland

³Division of Infectious Diseases and Hospital Epidemiology, Cantonal Hospital, Aarau, Switzerland

⁴Arud Centre for Addiction Medicine, Zurich, Switzerland

⁵Phenix Foundation, Geneva, Switzerland

⁶Addiction Care Foundation, St. Gallen, Switzerland

⁷Ingrado Addiction Service and Ticino Liver Centre SA, Lugano, Switzerland

⁸Department of Infectious Diseases, University Hospital, Bern, Switzerland

⁹Private Practice, Basel, Switzerland

¹⁰Geneva University Hospitals, Geneva, Switzerland

¹¹Lausanne University Hospital, Lausanne, Switzerland

Background:

We have shown the cost-effectiveness of hepatitis C Virus (HCV) infection screening in psychiatric inpatients independently of current drug use. However, we lack knowledge on mental disorders possibly triggering risk behavior for hepatitis C infection. This study evaluates whether specific mental disorders are associated with hepatitis C prevalence in the SAMMSU cohort in order to provide Swiss guidance.

Methods:

We analyzed data from 825 patients on opioid substitution treatment followed between 2014 to 2019 in the SAMMSU cohort. Follow-up consisted of annual visits for drug use, mental disorders (ICD-10 /F10-19) and HCV antibody screening among other health conditions. Disease-10 Risk ratios and stratification analyses were calculated using HCV prevalence and mental disorders (MD). Patients were followed longitudinally to evaluate the risks of drug use, HCV antibody prevalence, MD categories and risk ratios (RR) were calculated using patients with drug use only as reference group.

Results:

At least one additional MD was recorded in 72% of the 825 SAMMSU participants. Mood disorder was found in 45% with a RR = 0.90 [95%-CI: 0.75 - 1.09], personality and behavior disorder in 30% with a RR = 1.31 [95%-CI: 0.95 - 1.83] and 17% schizophrenia or delusional disorders, with a RR=0.69 [95%-CI: 0.53 - 0.92] for positive HCV antibodies, respectively. HCV prevalence was 75.97% in the reference group and 70.82% among patients with ≥ 2 MD.

In addition to history of opioid use disorder, 34% of patients reported use of benzodiazepines (RR=1.40 [95%-CI: 1.04 - 1.87]), 54% of cannabis and derivatives (RR=1.28 [95%-CI: 1.04 - 1.57]) and 46% of cocaine (RR=1.29 [95%-CI: 1.02 - 1.62]).

Conclusion:

Schizophrenia and delusional disorders were negatively associated with HCV, whereas personality and behavior disorders were positively associated with HCV prevalence among patients followed at the SAMMSU cohort.

Disclosure of Interest Statement:

Nothing to disclose.